Biobohemia, Inc. is a biotechnology company focused on development of cancer vaccines.
Biobohemia's lead technology is cell Antigenic Essence production via proteomics and cell culture technology, and which is a deep upgrade of cellular cancer vaccines. Cellular cancer vaccines are among the first types of cancer vaccines to be tested. They use a straightforward approach based on the well-known principle of vaccination – vaccinate with what you want to develop protection against. The significant possibilities of such vaccines have been described, but none have yet passed the clinical trial stage.
Antigenic essence technology is the revitalization of cellular vaccination, as antigenic essence exhibits all the identifying properties of cancer cells while also allowing for control of composition, purification from ballast substances (cellular 'noise'), and evasion of MHC restrictions. Therefore, antigenic essence technology allows upgrading of already discovered cellular compositions, as well as creation new ones.
Our antigenic essence technology platform is behind the development of the potential candidates for cancer vaccine, under the brand name SANTAVAC, that can be tuned against virtually any solid cancer. Our company is progressing the development of both prevention and therapeutic SANTAVAC vaccines.
Company Details
- Founded
- -
- Address
- 1 Broadway, Cambridge,massachusetts 02142,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.biobohemia.com
- HQ
- Cambridge, Massachusetts
- Competitors
- Chiesi USA, Inc..
Biobohemia, Inc. Questions
Biobohemia, Inc.'s website is https://www.biobohemia.com
Biobohemia, Inc.'s LinkedIn profile is https://www.linkedin.com/company/biobohemia
Biobohemia, Inc.'s industry is
Biotechnology Research
Biobohemia, Inc.'s top competitors are
Chiesi Usa, Inc..
Biobohemia, Inc.'s categories are Biotechnology Research
Biobohemia, Inc.'s founding year is 2019
